Section
NCT
Category
Hematological neoplasms
Subcategory
Hodgkin-Lymphome
Trial Type
First-Line-Therapy (Metastatic Disease/Hematology)
Description for experts
Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma
Description for laymen
Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma
JSON Data
{
"short_title": "INDIE",
"data_mode": "910",
"data_mode_number": "000000052",
"official_title": null,
"accrual_state": "running",
"therapeutic_value": "not_applicable",
"therapieansatz_value": "not_applicable",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "first",
"ctgov_number": null,
"eudract_number": "2021-000330-33",
"general_contact_email": "sal-aml-register@ukdd.de",
"general_contact_phone": "+49 351-45818380",
"hauptpruefer_dd_name": null,
"description_laie_de": "Individualisierte Immuntherapie f\u00fcr Patienten mit klassisschem Hodgkin Lymphom im intermedi\u00e4ren Stadium",
"description_laie_en": "Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma",
"description_expert_de": "Individualisierte Immuntherapie f\u00fcr Patienten mit klassisschem Hodgkin Lymphom im intermedi\u00e4ren Stadium",
"description_expert_en": "Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma",
"rechtsgrundlage_value": null,
"phase_amg_value": null,
"main_cat_id": 4,
"sub_cat_id": 27
}
